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Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by widespread 
small vessel vasculopathy, immune dysregulation with production of autoantibodies, 
and progressive fibrosis. There are only few reports available concerning ophthalmologi-
cal complications in the course of SSc, although ocular manifestations, e.g., dry eye syn-
drome (DES), occurs frequently and decreases the quality of life of these patients. Vascular 
endothelial growth factor (VEGF), the major pro-angiogenic factor, plays a key role in the 
pathomechanism of SSc. Although elevated levels of VEGF in sera have already been dem-
onstrated, VEGF analysis in tears of patients with SSc has not been performed in previous 
studies. VEGF in the tears of patients with SSc was found to be decreased by 20%, compared 
to healthy controls. The reason why the VEGF levels are not elevated in the tears of patients 
with SSc needs further investigations, as does the sera of the same patients. The cytokine 
array results revealed a shift in the cytokine profile characterized by the predominance of 
inflammatory mediators. Our current data depict a group of cytokines and chemokines, 
which play a significant role in ocular pathology of SSc; furthermore, they might function 
as excellent candidates for future therapeutic targets in SSc with ocular manifestations.
Keywords: systemic sclerosis, dry eye syndrome, tear, vascular endothelial growth factor, 
cytokine, tear sampling, total protein, enzyme-linked immunosorbent assay, cytokine 
array, multiplex bead assay
1. Introduction
There are few reports, mainly case reports, available concerning ophthalmological compli-
cations in the course of systemic sclerosis (SSc). Overall studies are even fewer involving 
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only a small number of patients, since SSc is a rare disease [1, 2]. Changes in the organ 
of vision are thought to be the consequences of systemic complications of scleroderma or 
adverse effects of the immunosuppressive treatment applied. Ocular symptoms may occur 
at any stage of the disease and may involve numerous ocular tissues. Their course can be 
clinically latent or very intensive. The most prevalent clinical manifestations of soft tissue 
fibrosis and inflammation in patients with SSc include increased tonus and telangiectasia 
of the eyelid skin. The most common lesions reported include periorbital edema, palpebral 
ectropion, and madarosis [3].
The most frequent ocular manifestation of SSc in our studies was dry eye syndrome (DES).
DES is a major healthcare problem because it affects the patient’s quality of life. DES in SSc is 
believed to be caused by fibrosis-related impairment of lacrimal gland secretion, namely, the 
reduction of the water portion of the tear film. Furthermore, lipid layer disorder is caused by 
chronic blepharitis and meibomian gland dysfunction (MGD), while increased evaporation of 
tears from the ocular surface is the consequence of restricted eyelid mobility and the consecu-
tive reduced blinking [2]. DES was recently redefined as a multifactorial disease of the tears 
and ocular surface that results in symptoms of discomfort, visual disturbance, tear film insta-
bility, and last but not least damage to the ocular surface [4]. Increased osmolality of the tear 
film [5] and inflammation of the ocular surface [6] are the two major characteristic features of 
this ocular surface disease. The most important laboratory findings [6] are increased levels of 
several inflammatory cytokines. Accordingly, tear cytokine levels are regarded as potential 
markers of inflammation in DES.
The ophthalmological manifestations in patients with SSc are frequently underestimated and 
not or not correctly treated. In order to better understand the ocular features and use this 
body fluid as a potential tool for monitoring these important biomarkers, we have turned our 
attention to tear investigations.
Precorneal tears as a biological fluid are very easily accessible with non- or very low-invasive 
methods at a relatively low cost. Tears not only lubricate the ocular surface carrying secreted 
molecules from corneal epithelial cells and tissues producing tear components but also rep-
resent the whole physiological status of the body. Due to the very limited amount of sam-
ples and the relative instability of the components, sample collection is a critical step in tear 
research and diagnostics.
Although tear analysis is of increasing interest in ophthalmology, no studies have investi-
gated tears of patients with SSc as yet, possibly because of the technical challenge posed by 
the extremely small sample volumes available [7].
Quantitative determination of tear proteins is of increasing interest in ophthalmology, but 
a technical problem still remains due to small tear sample volumes available on the one 
hand and the complexity of their composition on the other [7, 8]. Tear sampling performed 
either directly or indirectly is definitely a major challenge or has a most significant influ-
ence on the precision and reproducibility of the analytical results as seen in the summary 
below.
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1.1. Direct sampling methods
Direct sampling methods use microcapillary tubes [9] or micropipettes for sampling. This 
requires previous stimulation or instillation of different volumes of saline (100–200 μl) into 
the cul-de-sac and collecting after appropriate mixing. The procedure causes dilution and 
may not permit collection of samples from specific sites of the ocular surface [10].
Kalsow et al. investigated the tear cytokine response to multipurpose solutions in contact 
lens [11] wearing. Before tear collection, contact lens was removed, and then NST tears 
were collected from both eyes from the inferior lateral conjunctival cul-de-sac using a 10-μl 
flame-polished glass micropipette. The collection, a 5.5-μl tear volume, was immediately 
transported to a sterile 0.2-ml tube containing 49.5 μl of storage solution to produce a 1:10 
tear dilution for immediate storage at −80°C [11].
Guyette et al. compared low-abundance biomarker levels in capillary-collected NST tears 
and washout (WO) tears of aqueous-deficient and normal patients. 10-microliter polished 
micropipettes were used to collect tears from the inferior marginal strip, taking special care to 
minimize ocular surface contact. Tear collection rate was continuously monitored. Individual 
NST tear samples were collected in 10-min aliquots and immediately transferred to a sterile 
polymerase chain reaction (PCR) tube. An equal volume of assay buffer was added, and 
the sample was stored at −86°C. A total of at least 6.5-μl NST tears were collected from each 
study participant, and each 10-min aliquot was transferred into a separate PCR tube and 
put in the freezer without delay. Prior to WO tear sample collection, 10-μl sterile physi-
ologic saline solution was added to the lower conjunctiva by a digital pipette. The patient was 
instructed to gently close the eyes and avoid any eye movements for one minute. Tears were 
then collected using the same method as for NST samples, but a shorter collection time of 5 
min per aliquot was used to make up the 6.5-μl minimum volume required. Tear collection 
volume and time were continuously monitored to measure tear collection rate [12].
There have been several research projects focusing on dry eye syndrome, and nowadays the 
emphasis has shifted toward the role of inflammation in the anterior surface of the eye [13]. 
Since inflammatory mediators originating from various ocular surface sources and the main 
lacrimal gland do not constitute a totally homogenous mix, the way the tears are collected will 
influence the resulting biomarker profile. NST tear samples from the inferior marginal strip 
cover a broader spectrum of the sources, whereas ST samples contain a higher proportion 
of the lacrimal gland secretion [14]. Explicit protein profile differences between NST and ST 
tears demonstrate that these two sample types are not equivalent [15, 16]. Although NST tears 
represent specifically the inflammatory status of the ocular surface, the volume of NST tears is 
limited, especially in aqueous-deficient dry eye. Even though tear sampling frequently makes 
use of capillaries as they are less irritating and the resulting sample is an exact representative 
concentration of molecules, the main limitation of the method is the volume of sample (2–3 
μl) to be gained [17].
One way to increase the available tear sample volume is to add fluid (e.g., sterile saline) to 
the eye prior to sample collection, effectively “washing out” ocular surface molecules [18, 19]. 
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In an experimental dry eye study, Luo et al. collected tears from mice with tear fluid wash-
ing [20]. Tear fluid washings were collected by a method previously reported by Song et al. 
[21]. Briefly, 1.5 μl of phosphate buffered saline (PBS) containing 0.1% bovine serum albumin 
(BSA) was instilled into the conjunctival sac. The tear fluid and buffer were collected with 
a 10-μl volume glass capillary tube by capillary action from the tear meniscus in the lateral 
canthus. The 2-μl sample of tear washings was pooled from both eyes of each mouse and was 
stored at −80°C until zymography and enzyme-linked immunosorbent assay (ELISA) were 
performed.
Validity of the WO method depends on the extent to which it changes the NST tear biomarker 
profile. By determining tear sIgA, inducement of reflex tearing is easily detected because tear 
sIgA levels decrease with reflex tear flow rate [16]. Markoulli et al. found equal tear sIgA-total 
tear ratios in WO and NST tears, which suggests that WO tear samples do not significantly 
induce reflex tearing [19]. Guyette’s study evaluated WO tear collection as a replacement for 
microcapillary NST tear collection and applied this to compare biomarker levels between 
aqueous-deficient (AD) dry eye and non-AD patients [12, 15, 22].
1.2. Indirect methods
An indirect method means that collection of precorneal tear film (PTF) is carried out 
using absorbing supports such as Schirmer test strips (STS), filter paper disks, cellulose 
sponges, and polyester rods. STS collection is the most commonly used method among 
them [23].
Acera et al. analyzed the inflammatory markers in the PTF of patients with ocular surface 
disease. 10 μl of tear samples was collected by a Weck-Cel sponge [24]. The concentrations of 
IL-1β, IL-6, and pro-MMP-9 were measured by ELISA, and the MMP-9 activity was evaluated 
by gelatin zymography.
Inic-Kanada et al. compared ophthalmic sponges and extraction buffers for quantifying cyto-
kine profiles in tears using Luminex technology. They found that Luminex detection of cyto-
kine/chemokine profiles of tears collected with Merocel sponges may be useful in clinical 
studies, for instance, to assess cytokine profile evaluation in ocular surface diseases [25].
Samples obtained from the Schirmer test procedure have been found to have a higher 
mucus, lipid, and cellular content than microcapillary (MC) samples [26]. STS also suf-
fers from incomplete, nonuniform elution of proteins from the filter matrix [23]. Although 
micropipette and STS collection provide different biomarker profiles for a given donor, 
the correctly applied micropipette method has proved to be more consistent [27]. STS is 
widely applied as the volume of sample collected with this method is larger than other 
methods, but it can cause reflexive tearing due to irritation, which increases the volume 
of the samples, thus aggravating the detection of the investigated tear component(s), e.g., 
drug levels [9].
In comparative studies, the tears of the same patient are collected using several collection 
methods to determine the same biomarkers from the different tear samples.
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Green-Church et al. collected tears using small volume (1–5 μl) Drummond glass MC tubes 
with 1.6× slit-lamp magnification. Non-reflex tears were collected from the inferior tear prism 
without contact with the lower lid until a total of 5 μl had been collected. During a separate 
visit, tear collection was performed by placing an STS over the lower lid. The lid was canthus. 
The subject was instructed to close his/her eyes for the 5-min test duration; the wet length 
was not recorded but was observed to be within normal ranges in all cases. The STS was then 
placed in 1.6-ml amber Eppendorf tube and stored at 4°C until analysis [27].
Lee et al. used two collection techniques for the comparative analysis of polymerase chain 
reaction assay for herpes simplex virus 1 detection [28]. Tear samples were collected from the 
lower fornix using STS for 5 min, a method adopted in a previous study of Satpathy et al. [29]. 
The other collection method they used was micropipetting tears, after irrigating 100-μl saline 
in the lower fornix, a method that was described in a previous study of Markoulli et al. [19], 
who validated the “flush” tear collection technique as a viable alternative to basal and reflex 
tear collection.
2. “Main body of the paper”
The aims of our studies were the following:
1. To select an appropriate sampling method to investigate vascular endothelial growth fac-
tor (VEGF) and cytokines in tears of SSc patients.
2. To detect VEGF in tears of SSc patients.
3. To compare VEGF levels in tears of patients with SSc to those in healthy controls.
4. To determine a wider panel of cytokines and chemokines that have a role in immunopatho-
genesis and inflammatory processes in tears of patients with SSc.
5. To compare the levels of identified mediators in tears of these patients and controls and to 
select the most significantly differing ones for further investigations.
6. To determine the selected mediators with the help of a more sensitive and specific labora-
tory method in tears of both patients and controls.
2.1. Patients and healthy controls
In the first study, 43 patients with SSc (40 female and 3 men) and 27 healthy controls were 
included. In the second study, we enrolled 9 patients and 12 controls. Mean (SD) age of the 
patients was 61.85 (48–74) years. SSc was diagnosed based on the corresponding international 
criteria. Patients were enrolled from the outpatient clinic at the Department of Rheumatology. 
They went through ophthalmological examination and basal tear sample collection at the 
Department of Ophthalmology. None of the patients had secondary Sjögren’s syndrome. 
The healthy control groups were composed of age- and gender-matched volunteers with no 
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history of any autoimmune or ocular disorder. Patients did not take immunosuppressive 
medications at the time of the tear sampling.
Written informed consent was obtained from all patients and controls. Study protocol was 
approved by the local bioethics committee and followed the tenets of the declaration of 
Helsinki.
2.2. Tear sample collection
Unstimulated, open-eye tear samples were gently collected from the inferior temporal 
meniscus of both eyes, using glass capillary tubes (Haematokritkapillare, 75 μL, L 75 mm, 
Hirschmann Laborgerate, Germany), minimizing irritation of the ocular surface or lid margin 
as much as possible.
In the course of the first study, samples were collected between 11 a.m. and 16 p.m. by the 
same physician. Tear-secretion velocity was counted by dividing the volume of collected sam-
ple with time of secretion. Volume was calculated from the lengths of the fluid column in the 
capillary tube, measured with a vernier caliper, and from the known diameter of the tube. 
Time of tear collection was measured with a stopwatch.
In the course of the second study, tear collection was performed between 9 and 11 a.m.
Tears were transferred into low-binding-capacity Eppendorf tubes by the help of a sterile 
syringe and a needle, carried on dry ice to the laboratory and stored at −80°C until assess-
ment. The samples were obtained from both eyes of each individual and were pooled due to 
the small volume available.
2.3. Quantification of total protein and VEGF levels in tear samples of patients with SSc
First, as a point of reference for VEGF, total tear protein concentrations were determined 
using the microplate method of the bicinchoninic acid (BCA) Protein Assay Kit (Pierce 
Biotechnology, Rockford, USA) adapted to a 384-well microplate due to the small sample 
amounts. The kit is a two-component, high-precision, detergent-compatible assay. Total pro-
tein concentration determination was based on color intensity measurement proportional to 
the peptide bound and the protein provided with the reagent set. The reaction absorbs visible 
light, namely, the wavelength 562 nm.
We used a human VEGF immunoassay kit by Quantikine (R&D Systems, Minneapolis, MN, 
USA) for the quantitative determination of VEGF in tear fluid. This assay employs the quan-
titative sandwich enzyme immunoassay technique.
2.4. Membrane array and multiplex bead analysis of tear cytokines in SSc
To remove cells, cellular debris, and contaminant particles, tear samples were centrifuged (10 
min, 15,000 rpm, 4°C) prior to use.
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Tear samples of controls and patients were used for cytokine profiling. The relative levels of 
102 different cytokines were determined by Proteome Profiler Human XL Cytokine Array Kit 
(R&D Systems) using 50-μl samples according to the manufacturer’s instructions. The pixel 
density in each spot of the array was determined by ImageJ software.
Alternatively, the absolute levels of MCP-1, complement factor D (CFD), IP-10, and 
C-reactive protein (CRP) were determined from diluted tear samples (CFD, MCP-1, and 
CRP, 1:10; IP-10, 1:40) by Human Luminex Performance Assays (R&D Systems) according 
to the manufacturer’s instructions. The measurement was run on Bio-Plex 200 Systems (Bio-
Rad) workstation.
2.5. Results
2.5.1. Vascular endothelial growth factor in tear samples of patients with systemic sclerosis
The average tear secretion velocity in patients was 4.53 μl/min with a median of 3.8 μl/min 
(1.5–25.6).
Duration of tear sample collection from patients varied between 20 and 313 s, until 5 μl, the 
minimally required volume was reached.
The average collected tear fluid volume was 10.4 μl (1.6–31.2) in patients and 15.63 μl (3.68–
34.5) in controls.
In tear samples of patients with SSc, the average total protein level was 6.9 μg/μl (1.8–12.3), and 
the average concentration of VEGF was 4.9 pg/μl (3.5–8.1) in the case of basal tear secretion.
Control tears contained on average 4.132 μg/μl (0.1–14.1) protein and 6.15 pg/μl (3.84–12.3) 
VEGF.
2.5.2. Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis
2.5.2.1. Cytokine array results
Nonstimulated tear cytokine profiles of the control groups and patients with SSc were ana-
lyzed by cytokine array detecting 102 different cytokines. Array results revealed a shift in 
cytokine profile characterized by the predominance of inflammatory mediators. The fol-
lowing 9 out of the 102 analyzed molecules were significantly increased in tears of patients 
with SSc: complement factor D (CFD), chitinase-3-like protein 1 (CHI3L1), C-reactive pro-
tein (CRP), epidermal growth factor (EGF), interferon-γ-inducible protein 10 (IP-10, also 
called CXCL-10), monocyte chemoattractant protein-1 (MCP-1), monokine induced by 
gamma interferon (MIG), matrix metallopeptidase 9 (MMP-9), and vitamin D binding pro-
tein (VDBP) (Table 1).
Integrated density values were normalized to positive control spots and total protein content 
of the samples. Cytokine array data are representative of four control and four SSc samples.
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2.5.2.2. Multiplex cytokine bead assay results
By using the more sensitive and more specific Luminex bead assay, 4 selected molecules were 
determined in tears of 9 healthy controls and 12 patients with SSc.
Based on the Luminex bead results, mean CRP levels were 103.44 (3.57–359.02) μg/mg protein 
in tears of patients with SSc and 7.41 (0.87–18.03) μg/mg protein in tears of healthy controls.
Mean IP-10 levels were 564.78 (252.62–1107.2) μg/mg protein in tears of patients with SSc and 
196.118 (101.66–514.37) μg/mg protein in tears of healthy controls.
Mean MCP-1 levels were 2626.83 (457.84–5619.4) μg/mg protein in tears of patients with SSc 
and 661.27 (397.87–1171.4) μg/mg protein in tears of healthy controls.
Mean CFD levels were 15.27 (5.00–35.28) μg/mg protein in tears of patients with SSc and 23.31 
(5.18–106.63) μg/mg protein in tears of healthy controls.
Except for CFD all results were significant at p = 0.01 for CRP, p = 0.001 for IP-10, and p = 0.01 
for MCP-1, respectively.
Values represent the mean (±SD) of the 9 control and 12 patient samples, which are the fold 
change of normalized cytokine levels.
The difference between total protein values of control and SSc tear samples was not significant 
(p = 0.37263). Mean total protein was 818.46 (779.94–1162.4) μg/ml in tears of patients and 
872.46 (771.78–1359.5) μg/ml in tears of controls.
Based on both the cytokine array and the multiplex bead assay results, concentrations of IP-10 
showed the most significant difference in tears of patients and controls.






Significance of the 
difference (p)
CFD 50.35 (23.17–53.76) 22.33 (18.39–24.75) 0.002072
CHI3L1 94.41 (31.9–95.98) 31.06 (20.37–45.85) 0.000000
CRP 25.98 (15.28–53.16) 4.55 (4.35–4.66) 0.018250
EGF 53.42 (34.86–70.23) 34.04 (20.42–47.61) 0.032818
IP-10 123.42 (93.81–152.35) 21.99 (12.12–29.01) 0.000000
MCP-1 19.93 (5.38–42.44) 1.72 (1.44–2.27) 0.044726
MIG 22.85 (5.6–64.14) 3.58 (3.29–3.88) 0.033787
MMP-9 49.10 (4.24–129.04) 12.74 (10.29–17.56) 0.000068
VDBP 31.35 (11.87–64.68) 10.18 (8.3–13.84) 0.019733
Mean total protein values did not differ significantly in tears of patients and controls. Mean total protein value was 
40.9239 μg/ml in tears of patients with SSc and 42.536 μg/ml in tears of healthy controls (p = 0.863604).
Table 1. Normalized densities of cytokines and chemokines in patients with SSc and healthy controls.
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2.6. Discussion
Although ocular manifestations in systemic autoimmune diseases have significant debilitat-
ing effects, tear analysis has been missing from the repertoire of investigations. Since tears 
represent the local homeostasis of the ocular surface better than serum, this makes tears ideal 
for assessing ocular pathology in the disease. There are two possible ways for cytokines to 
appear in the precorneal tear film. Some are locally produced and diffuse into the tear film 
from the corneal and conjunctival epithelia; others leak into the tear film from the conjuncti-
val blood vessels [30]. Tear investigation is a challenging research field; though sample col-
lection is noninvasive, it has an almost insurmountable limitation, the quantity of the sample 
obtainable [31].
Tear investigation studies have been performed in different ocular and systemic disorders [30, 
32, 33]. Leonardi et al. assessed multiple mediators, such as cytokines, matrix metalloprote-
ases, and angiogenic and growth factors in tears of patients with vernal keratoconjunctivitis. 
These analyses identified previously unreported factors in tears of patients, including MMP-3 
and MMP-10 and multiple proteases, growth factors and cytokines, which may all be instru-
mental in the pathogenesis of conjunctival inflammation. Different molecules were identified 
in human tear samples that were involved in the development and maintenance of corneal 
neovascularization. Concentrations of the pro-angiogenic cytokines such as IL-6, IL-8, VEGF, 
MCP-1, and Fas ligand were determined in blood and tear samples using flow cytometry-
based multiplex assay. These investigations resulted in significantly higher concentrations 
of pro-angiogenic cytokines in human tears compared to their concentrations in serum; fur-
thermore highest levels were revealed in basal tear samples [30]. These findings lend further 
support to the importance of our current studies.
After reviewing the literature on direct and indirect tear sampling methods in various ocu-
lar and systemic disorders, we have chosen the microcapillary method for tear sampling in 
patients with SSc, since it is safely applicable for the collection of nonstimulated tears. In order 
to transfer the tear fluid from the microcapillary tube to the collection tube, we applied a ster-
ile syringe and a needle. This tear sampling method proved to be suitable for our experiments 
on tear cytokines.
2.6.1. VEGF in tear samples of patients with SSc
VEGF is one of the components of normal tear fluid [34]. Vesaluoma et al. determined 
VEGF concentrations in healthy tears. The median VEGF concentration was 5 pg/μl (4–11) 
consistent with our results, as control tears contained an average of 6.15 pg/μl (3.84–12.3) 
VEGF [35].
They calculated the average tear fluid secretion in healthy controls, which was 8.1 μl/min 
(0.7–20.8), using the same tear collecting method as we did in our study. Results show 
that patients with SSc have significantly decreased tear secretion that could be explained 
by DES, which is a probable sequel of the disease or to the side effects of the therapeutic 
drugs [36].
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Tear-secretion velocity was lower by 67% in patients with SSc than in healthy controls. The 
difference was significant (p < 0.01). The reason for this sign could be explained by the patho-
physiology of the disease, namely, fibrotic processes of the lacrimal gland.
Total protein values in patients with SSc were higher by 42% than in healthy controls. This 
may indicate that total protein production—or simply protein concentration, since patients 
with SSc have a decreased tear secretion velocity—is only increased because of the smaller 
tear volume. VEGF in the tears of patients with SSc decreased by 20%, which can be explained 
also by the decreased tear secretion of patients [36].
The question why contrary to our expectations VEGF levels are not higher in patients with SSc 
than in the healthy group needs further investigation.
2.6.2. Membrane array and multiplex bead analysis of tear cytokines in SSc
Based on our cytokine array results, nine cytokines and chemokines had significantly higher 
levels in tears of patients with SSc. This screening method was performed for the assort-
ment of 102 cytokines, selecting the most relevant ones in the pathogenesis of SSc for further 
experiments. All molecules which appeared to be significantly higher in tears of patients are 
molecular players of the immune responses and inflammatory processes, which confirms the 
presence of ocular surface inflammation in patients with SSc possibly as a consequence of 
DES [36].
CHI3L1, a protein which takes part in the processes of inflammation and tissue remodeling, 
has not been previously described in relation to the pathomechanism of SSc. We have found 
elevated levels of CHI3L1 in patients with SSc. This result correlates well with the fact that 
inflammation and tissue injury caused by hypoxia and oxidative stress are always present in 
the course of SSc.
In fact, different pathways may lead to vascular dysfunction processes in SSc, such as direct 
vascular damage or pro-inflammatory responses. Studies in different diseases have shown 
functional links between activated complement molecules and these pathways. CFD, a serine 
protease, also known as adipsin, plays a key role in these processes [37, 38]. CFD is the rate-
limiting enzyme in the activation cascade of the alternative pathway, and its level in the blood 
is quite low. Our cytokine array results showed increased CFD levels, which confirm the role 
of the complement system in the ocular pathology of SSc.
Levels of EGF were also elevated in tear samples of patients with SSc. EGF is a growth factor 
that stimulates cell growth, proliferation, and differentiation [39]. Elevation of EGF may be 
explained by the above processes of vasculopathy. The next molecule, which appeared to be 
higher in patients’ tears, is matrix metallopeptidase-9 (MMP-9). As a protease of the MMP fam-
ily, it is involved in the breakdown of extracellular matrix in normal physiological processes, 
such as embryonic development, reproduction, angiogenesis, bone development, wound heal-
ing, cell migration, as well as in pathological processes, such as intracerebral hemorrhage, 
arthritis, and metastasis [40–42]. In a study of Kim et al., serum MMP-9 concentrations were 
found to be elevated in patients with SSc correlating well with skin scores [43]. Their results 
suggest that increased MMP-9 concentrations may be due to their overproduction by dermal 
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fibroblasts and also that the enhanced production of MMP-9 may contribute to fibrogenic 
remodeling during the progression of skin sclerosis in SSc. Our results of tear cytokine array 
are parallel with the finding that MMP-9 is increased in the course of SSc.
In a previous study, expression of antiangiogenic chemokines and their receptors were deter-
mined in the sera and skin of patients with SSc [44]. Based on their results, MIG and its recep-
tor are elevated in serum and highly expressed in the skin of patients with SSc. We have 
also found increased levels of MIG in tear samples of patients, which confirm the fact that 
dysregulated angiogenesis is an important feature in the pathomechanism of SSc. The next 
protein that appeared to be higher is VDBP, a member of the albumin gene family. VDBP is 
a multifunctional protein found in plasma, ascitic and cerebrospinal fluid and on the surface 
of many cell types. It binds to vitamin D and its plasma metabolites and transports them to 
target tissues [45]. Others have measured significant quantities of VDBP-actin complexes in 
the plasma following injury [46]. The presence of tissue injury is likely to be the explanation 
of our results, namely, the elevated levels of VDBP in the tears of patients with SSc.
Based on our results of multiplex bead assay, the three molecules that showed significant dif-
ferences in tears of patients and controls were IP-10, MCP-1, and CRP. Previous studies have 
already demonstrated elevated levels of these markers in the sera of patients with SSc.
General markers of inflammation, such as CRP, are expected to be higher in a disease like 
SSc. In earlier trials, CRP appeared to be elevated in the sera of patients with SSc and was 
associated with poor survival. Therefore, it may be a useful indicator of disease activity and 
severity in SSc [47, 48].
Another inflammatory chemokine, IP-10, also called CXCL-10, has often been investigated in 
SSc studies [44, 49, 50]. IP-10 has an angiostatic function as it suppresses neovascularization; 
furthermore, it is involved in immune regulation [51].
Recent reports have shown that the serum and/or the tissue expressions of IP-10 are increased 
in various bacterial, viral, fungal, and protozoal infections [52] and also in autoimmune 
diseases like rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, auto-
immune thyroid diseases, type 1 diabetes mellitus, Addison’s disease, and SSc [50, 53–55]. 
CXCL10 is secreted by CD4+, CD8+, natural killer and natural killer T cells and is dependent 
on interferon-γ. CXCL10 can also be secreted by several other cell types, including endothe-
lial cells, fibroblasts, keratinocytes, thyrocytes, preadipocytes, etc. Detecting a high level of 
CXCL10 in peripheral fluids is therefore a marker of host immune response [48], which cor-
relates well with our results of cytokine bead assay measurements.
Finally, MCP-1, which is a key participant of the fibrotic processes in SSc, also appeared to 
be higher in patients’ tears. MCP-1, which recruits monocytes, memory T cells, and dendritic 
cells to the sites of inflammation, is produced by either tissue injury or infection [56]. It is 
known as one of the most pathogenic chemokines during the development of inflammation 
and fibrosis in SSc [57]. MCP-1 is not only a chemoattractant molecule for monocytes and T 
cells, but it also induces Th2 cell polarization and stimulates collagen production by fibro-
blasts [58]. Hasegawa et al. have previously shown that serum MCP-1 levels are elevated 
when the skin and lung are affected in patients with SSc [59]. It has also been reported that 
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cultured dermal fibroblasts from patients with SSc show augmented expressions of MCP-1 
mRNA and protein [60].
Of the last three molecules, IP-10 and MCP-1 are the ones whose molecular characteristics 
single them out as potential candidates for therapies against the pathological consequences 
of diseases such as SSc.
2.7. Novel findings
1. After reviewing the literature of tear sampling techniques, we labored the adequate tear 
sampling methods and collected tears with capillary system from SSc patients in order to 
investigate VEGF molecule and cytokines.
2. We were the first to demonstrate the presence and concentration of VEGF, an element that 
plays an important vascular role in the pathogenesis of SSc, with the help of a method that 
is based on a quantitative sandwich immunoassay technique.
3. By the help of our survey, which is based on a quantitative sandwich immunoassay tech-
nique, we were able to verify a 20% reduction in the VEGF concentration in tears of SSc 
patients compared to healthy controls.
4. We were the first to establish a wide cytokine profile in tears of SSc patients using an array 
that monitors 102 cytokines simultaneously.
5. Based on our cytokine array results, we revealed that 9 out of the 102 cytokines and 
chemokines had significantly higher levels in tears of patients with SSc. All of them are 
molecular players of the immune responses and the inflammatory processes. These find-
ings legitimate the existence of ocular surface inflammations which are quite frequent in 
patients with SSc. In addition, they are in accordance with former study results regarding 
the pathomechanism of SSc.
6. By using a highly sensitive and specific multiplex bead assay, we were the first to dem-
onstrate increased levels of IP-10, MCP-1, and CRP in tear samples of patients with SSc. 
Previous studies have already demonstrated elevated levels of these biomarkers in the sera 
of these patients; therefore tear analysis is to be raised as a potential means in dealing with 
diagnostic, prognostic, and maybe even therapeutic challenges of SSc.
2.8. Future plans
Angiogenesis impairment in SSc has been proved by several researchers. A number of serum 
investigations have been carried out regarding this phenomenon, but there are only scant 
data concerning tears of SSc patients.
The issue why the VEGF levels are not higher in SSc patients than in the healthy group needs 
further investigation. Other biochemical methods, like PCR, would be feasible to confirm 
array results. Furthermore, a longer-term prospective study in a larger population with exten-
sion of the ophthalmological examinations is needed to confirm clinical utility.
Systemic Sclerosis148
Our current data depict a group of inflammatory mediators, which may play a significant 
role in ocular pathology of SSc. Monitoring these factors in the tears of patients with SSc 
can be a noninvasive alternative to serum investigation. Additionally, in patients with ocular 
manifestations, such as DES, tear analysis is far more informative; it provides information of 
the ocular surface; hence it could help us choose the appropriate treatment, in particular arti-
ficial tears or anti-inflammatory eye drops [36]. Further studies are needed to understand the 
signaling pathways regulating pro-inflammatory cytokines, with the aim of developing new 
interventions against autoimmune diseases mediated by cytokines and chemokines, as well 
as inventing novel therapeutic possibilities for the ocular manifestations of SSc. New inflam-
matory mediators are to be searched that might function as excellent candidates for future 
therapeutic targets in SSc with ocular manifestations.
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CD Cluster of differentiation
CFD Complement factor D
CHI3L1 Chitinase-3-like protein 1
CRP C-reactive protein
CXCL Chemokine (C-X-C motif) ligand
DES Dry eye syndrome
EGF Epidermal growth factor
ELISA Enzyme-linked immunosorbent assay
IFN Interferon
IL Interleukin
ILD Interstitial lung disease
IP-10 Interferon gamma-induced protein-10
MC Microcapillary tubes
MCP Monocyte chemoattractant protein
MGD Meibomian gland dysfunction
MIG Monokine induced by gamma interferon
MMP Matrix metalloproteinase
mRNA Messenger ribonucleic acid
NST Nonstimulated tear
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PCR Polymerase chain reaction
PTF Precorneal tear filmRNARibonucleic acid
RNP Ribonucleoprotein
sIgA Secretory immunoglobulin A
SSc Systemic sclerosis
ST Stimulated tear
STS Schirmer test strip
TGF-β Transforming growth factor-beta
TNF-α Tumor necrosis factor-alpha
TRIM Tripartite motif
VDBP Vitamin D binding protein
VEGF Vascular endothelial growth factor
WO Washout
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